Pharmaceutical company Actavis Plc has won U.S. approval to purchase Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday. The deal was valued at about $25 billion when it was announced in February.
Shares of ACT fell by 0.1% or $-0.22/share to $223.05. In the past year, the shares have traded as low as $121.12 and as high as $230.77. On average, 2345070 shares of ACT exchange hands on a given day and today's volume is recorded at 6323528.
Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. Shares of FRX fell by 0.77% or $-0.77/share to $99.00. In the past year, the shares have traded as low as $40.98 and as high as $100.88. On average, 2393310 shares of FRX exchange hands on a given day and today's volume is recorded at 11098110.
Source
